Clinical Scorecard: Loss of Epithelium RAD50 Exacerbates Ulcerative Colitis through IL-6-Driven JAK1/2-STAT3 Pathway and Facilitates Colitis-Associated Cancer Development in Murine Models

At a Glance

Key Highlights

• RAD50 expression is reduced in human IBD and CAC tissues and mouse models, correlating with increased DNA damage.
• RAD50 deletion in intestinal epithelial cells sensitizes mice to DSS-induced colitis and promotes AOM-DSS-induced colon tumor development.
• RAD50 interacts with STAT3 to inhibit its phosphorylation, disrupting the IL-6-JAK1/2-STAT3-IL-6 feed-forward loop and suppressing inflammation.

Guideline-Based Recommendations

Diagnosis

• Assess RAD50 expression and DNA double-strand breaks (γ-H2AX) in colon tissues of UC and CAC patients to evaluate disease progression.

Management

• Consider targeting the IL-6-JAK1/2-STAT3 pathway pharmacologically to alleviate colitis symptoms, especially in RAD50-deficient contexts.
• Pharmacological STAT3 inhibition (e.g., C188-9) may relieve colitis and reduce tumor development in RAD50-deficient models.

Monitoring & Follow-up

• Monitor inflammatory cytokine levels, particularly IL-6, and STAT3 activation status during disease progression and treatment.
• Evaluate DNA damage markers and epithelial cell proliferation as indicators of disease severity and cancer risk.

Risks

• RAD50 deficiency increases susceptibility to severe colitis and promotes colitis-associated cancer development due to persistent DNA damage and inflammatory signaling.

Patient & Prescribing Data

Patients with ulcerative colitis at risk for colitis-associated cancer

Increasing RAD50 levels or inhibiting the IL-6-JAK1/2-STAT3 pathway may provide therapeutic benefit; STAT3 inhibitors have shown efficacy in murine models.

Clinical Best Practices

• Evaluate DNA damage repair protein expression (RAD50) in intestinal epithelium as part of UC and CAC risk assessment.
• Target IL-6-mediated inflammatory signaling pathways to control disease progression and reduce cancer risk.
• Use murine models with epithelial-specific RAD50 deletion to study novel therapeutic interventions for UC and CAC.

References

• Original Article